ALN-APOC3 in Adult Participants With Dyslipidemia

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

136

Participants

Timeline

Start Date

January 27, 2025

Primary Completion Date

July 5, 2027

Study Completion Date

July 5, 2027

Conditions

Dyslipidemia

Interventions

DRUG

ALN-APOC3

Administered as per the protocol

DRUG

Matching Placebo

Administered as per the protocol

Trial Locations (1)

RECRUITING

Arensia Exploratory Medicine at the Republican Clinical Hospital, Chisinau

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY